Business Wire

Telecable and Sagemcom Launch an Android TVTM 4K Set-Top Box for Telecable tedi Service

Del

Within the framework of its TV offer, Telecable launched last month its new Android TV 4K tedi set-top box, designed and manufactured by Sagemcom. This new set-top box, integrating the latest cutting-edge technologies gives access to a complete TV and multimedia entertainment offer.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170913005592/en/

The tedi 4K STB enables to access over hundred TV channels, including the ones in 4K. When the product is connected to a 4K TV screen, the subscriber benefits from a crystal clear picture with four times the resolution of Full HD. The tedi application, developed by Telecable, brings a seamless browsing between TV programs, recordings in the cloud (network PVR), 7-day catch-up TV, time-shifting, advanced search, access to a VOD catalogue of more than 5000 titles with personalized recommendations and suggestions of contents.

Thanks to its embedded certified Android TVTM operating system, STB accesses thousands of downloadable applications through Google PlayTM, such as YouTubeTM , including for 4K contents, Wuaki TV and hundreds of games. An application allows turning subscriber’s smartphone into a remote control for the 4K tedi STB and to perform voice search for contents. Last but not least, support of Google CastTM enables screen sharing for contents.

Sagemcom designed and manufactured this STB around the 4K UHD BCM7252S SoC of Broadcom, and also carried out the integration and the certification of Android TV operating system that manages all the applications available on the product, as well as the integration of the tedi application. Finally, the device is also certified in terms of security for the protection of sensitive assets, both those proposed by telecable and those available in the Android universe.

“We are proud to launch with Telecable this new 4K tedi set-top box, offering an enriched TV experience thanks to the Android TV operating system and the available apps”, comments Olivier Taravel, Deputy Chief Executive Officer of Sagemcom Broadband. “At the cutting edge of technology, 4K UHD set-top boxes are key products for the company. Sagemcom relies on a strategic partnership with Broadcom to propose our clients a full range of always more powerful and innovative 4K STBs, including latest generation of Android TV devices.”

Aitor Markaida, General Manager of Telecable says: “As the leading cable television operator in Asturias, we are focus on offering our customers the best product with innovative solutions and improved services. The new device responds to the demands of our customers who are asking for 4k contents and a new way of watching television that combines liveTV, advance features for on-demand contents and applications. Our experience in the development of the 4K tedi set-top box with Sagemcom allows us to achieve this goal. We are proud to say that our new 4K tedi set-top box is one of the most innovative television devices”.

About Sagemcom

A French high-tech group of international dimensions, Sagemcom operates on the broadband (digital home, set-top boxes, Internet routers, telephony and multimedia terminals), smart city (smart meter, smart grid, smart infra, smart sites and smart services), and Internet of Things markets.
With revenue of around 1.6 billion euros, Sagemcom employs 4000 people on five continents and ships every year more than 25 million terminals. Sagemcom aims to remain a world leader in communicating terminals with high added value.

www.sagemcom.com // www.facebook.com/SagemcomOfficial //

About Telecable

Telecable, company that has recently joined in the Euskaltel Group, is the leading cable operator in the region of Asturias (Spain), which provides television, mobile, fixed telephony and high speed internet access services. The company, a key player in the development of the Asturian information society has over 75% market share in pay television, 28% in fixed, 43% in broadband and 17% in mobile. Telecable continues expanding its services based on the technological advantage of the optical fiber, having deployed more than 3.000 Km. of optical fiber in the Asturian territory.

Android TV, Google Play, YouTube and Google Cast are trademarks of Google, Inc.

Contact information

Media contacts:
Telecable
María ADARO GARCIA, tel. +34 984 191000
madara@telecable.com
or
Sagemcom
Sylvaine COULEUR, tel. +33 6 99 37 63 48
presse@sagemcom.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting20.10.2018 22:30Pressemelding

Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a late-breaking poster at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis. Positive efficacy data from FINCH 2 were previously announced in September 2018. The data show statistically significant improvements in the proportion of patients achieving a range of clinical efficacy endpoints, including the proportion of patients achieving American College of Rheumatology 20 percent (ACR20, primary endpoint), 50 percent

Manchester United and True Religion Launch Denim Range19.10.2018 17:37Pressemelding

Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion

Arch Insurance Announces Strategic Leadership Changes19.10.2018 13:10Pressemelding

Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These

Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 12:00Pressemelding

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an

Vertex Receives European CHMP Positive Opinion for KALYDECO® (ivacaftor) to Treat Patients With Cystic Fibrosis Aged 12 to <24 months With Certain Mutations in the CFTR Gene19.10.2018 11:54Pressemelding

Vertex Pharmaceuticals (Europe) Limited today announces that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for KALYDECO® (ivacaftor) to include the treatment of people with cystic fibrosis (CF) aged 12 to <24 months who have at least one of the following nine mutations in their cystic fibrosis transmembrane conductance regulator (CFTR) gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. If the European Commission issues a favorable adoption of the EMA CHMP opinion for the extension of indication, ivacaftor will be the first and only medicine approved in Europe to treat the underlying cause of CF in patients aged 12 to <24 months, who have specific mutations in the CFTR gene. “Cystic fibrosis is a chronic, progressive disease that is present at birth, with symptoms often occurring in infancy, so early treatment is crucial to deliver the best possible outcomes for patients,” said Reshma Kewalr

Schlumberger Announces Third-Quarter 2018 Results19.10.2018 11:00Pressemelding

Schlumberger Limited (NYSE: SLB) today reported results for the third quarter of 2018. (Stated in millions, except per share amounts) Three Months Ended Change Sept. 30, 2018 Jun. 30, 2018 Sept. 30, 2017 Sequential Year-on-year Revenue $8,504 $8,303 $7,905 2% 8% Pretax operating income $1,152 $1,094 $1,059 5% 9% Pretax operating margin 13.5% 13.2% 13.4% 36 bps 15 bps Net income - GAAP basis $644 $430 $545 50% 18% Net income, excluding charges & credits* $644 $594 $581 8% 11% Diluted EPS - GAAP basis $0.46 $0.31 $0.39 48% 18% Diluted EPS, excluding charges & credits* $0.46 $0.43 $0.42 7% 10% North America revenue $3,189 $3,139 $2,602 2% 23% International revenue $5,215 $5,065 $5,147 3% 1% North America revenue, excluding Cameron $2,572 $2,546 $2,086 1% 23% International revenue, excluding Cameron $4,559 $4,387 $4,430 4% 3% *These are non-GAAP financial measures. See section below entitled "Charges & Credits" for details. Schlumberger Chairman and CEO Paal Kibsgaard commented, “Our third